KRESLADI

Rocket Pharmaceuticals, Inc.🇺🇸 United States

FDA Page

Effective Date: Jul 1, 2026
Approval ID: 97db9c3c-20c2-4dad-890c-bc821805421f
Products: 0 registered
Version: 3

Regulatory Information

Labeling Type

CELLULAR THERAPY

Status

Approved

Full Title

These highlights do not include all the information needed to use KRESLADI safely and effectively. See full prescribing information for KRESLADI. KRESLADI (marnetegragene autotemcel) suspension for intravenous infusion Initial U.S. Approval: 2026

Quick Stats

Total Products0

Labelers1

Label Sections16

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.